What's Next In: Drug Delivery - Pharmaceutical Technology

Latest Issue

Latest Issue
PharmTech Europe

What's Next In: Drug Delivery

Pharmaceutical Technology

5. S. Kommareddy, S.B. Tiwari, and M.M Amiji, "Long-Circulating Polymeric Nanovectors for tumor-selective Gene Delivery," Technol. Cancer Res. Treat. 4 (6), 615-625 (2005).

6. V.P. Torchilin. "Multifunctional Nanocarriers," Adv. Drug. Deliv. Rev. 58 (14), 1532-1555 (2006).

7. E. Wagner, "Programmed Drug Delivery: Nanosystems for Tumor Targeting," Expert Opin. Biol. Ther. 7 (5), 587-593 (2007).

8. V. Weissig and V.P. Torchilin. "Drug and DNA delivery to Mitochondria," Adv. Drug Deliv. Rev. 49 (1), 1-2 (2001).

9. A. K. Daly, "Individualized Drug Therapy," Curr. Opin. Drug Discov. Devel. 10 (1), 29-36 (2007).

10. J. Woodcock, "The Prospects for "Personalized Medicine" in Drug Development and Drug Therapy," Cli. Pharmaco.l Ther. 81, 164-169 (2007).

Industry experts give their predictions for the next 30 years. Read Editor-in-Chief Michelle Hoffman's introduction here. See what's next in:

Strategy and Regulation
Solid-Dosage Formulation
Drug Delivery
Analytical Testing
Information Technology


blog comments powered by Disqus
LCGC E-mail Newsletters

Subscribe: Click to learn more about the newsletter
| Weekly
| Monthly
| Weekly

FDASIA was signed into law two years ago. Where has the most progress been made in implementation?
Reducing drug shortages
Breakthrough designations
Protecting the supply chain
Expedited reviews of drug submissions
More stakeholder involvement
Reducing drug shortages
Breakthrough designations
Protecting the supply chain
Expedited reviews of drug submissions
More stakeholder involvement
View Results
Eric Langerr Outsourcing Outlook Eric LangerRelationship-building at Top of Mind for Clients
Cynthia Challener, PhD Ingredients Insider Cynthia ChallenerRisk Reduction Top Driver for Biopharmaceutical Raw Material Development
Jill Wechsler Regulatory Watch Jill Wechsler Changes and Challenges for Generic Drugs
Faiz Kermaini Industry Insider Faiz KermainiNo Signs of a Slowdown in Mergers
CMOs and the Track-and-Trace Race: Are You Engaged Yet?
Ebola Outbreak Raises Ethical Issues
Better Comms Means a Fitter Future for Pharma, Part 2: Realizing the Benefits of Unified Communications
Better Comms Means a Fitter Future for Pharma, Part 1: Challenges and Changes
Sandoz Wins Biosimilar Filing Race
Source: Pharmaceutical Technology,
Click here